Menu ×

HEALTHCARE & PHARMACEUTICAL

Interchangeable Biosimilars Market Segmentation by Disease Type (Crohn’s Disease, Ulcerative Colitis, Psoriasis, Diabetes, Cancer, and Others); and by Distribution Channel (Hospital, Retail Pharmacies, and Others) – Global Demand Analysis & Opportunity Outlook 2031

  • Text Size:

Extensive insights into the Growth of Interchangeable Biosimilars Market amidst COVID-19

Get the detailed impact analysis of COVID-19 that has disrupted the entire world and affected many industries.

Request Insights


IN THE NEWS

  • March 10, 2022: Samsung Bioepis Co., Ltd. and Biogen Canada Inc. announced the approval of BYOOVIZ by Health Canada. BYOOVIZ is a biosimilar referencing LUCENTIS (ranibizumab).

  • December 20, 2021: Sandoz International GmbH, global leader in generic and biosimilar medicines, announced the submission of Biologics License Application for biosimilar trastuzumab to the US Food and Drug Administration (FDA).

Global Interchangeable Biosimilars Market Highlights over 2022 – 2031

The global interchangeable biosimilars market is estimated to grow at a CAGR of ~9% over the forecast period, i.e., 2022 – 2031. Interchangeable biosimilars are the medical products that can be used as an alternative to the reference products, without the physician’s prescription. It is similar to the use of generic medicines as a replacement of branded medications. The growth of the market can be attributed to the increasing launch of new products, along with the high medical research investments across the globe. As per the data by the World Bank, 2.203% of the global gross domestic product (GDP) was spent on R&D activities in 2018. The growing research and development activities in the healthcare sector is further estimated to boost the market growth. Moreover, various government initiatives to promote the use of interchangeable biosimilars is anticipated to advance the growth of the market. For instance, the U.S. Food and Drug Administration (FDA) has approved biosimilar medications to treat certain conditions, including, cancer, diabetes, Crohn’s disease, colitis, rheumatoid arthritis, and psoriasis. In addition to this, interchangeable biosimilars are easily accessible and pocket friendly, which is a major factor behind its growing adoption amongst patients.

Interchangeable Biosimilars Market Graph

Get more information on this report: Request Sample PDF

The global interchangeable biosimilars market is segmented by disease type into Crohn’s disease, ulcerative colitis, psoriasis, diabetes, cancer, and others, out of which, the cancer segment is anticipated to hold a substantial revenue share over the forecast period. The growth of the segment can be accounted to the increasing prevalence and mortality rate of cancer. According to the data by the World Health Organization (WHO), cancer accounted for nearly 10 million deaths in 2020 globally.

Major Macro-Economic Indicators Impacting the Market Growth

Global Healthcare Expenditure per Capita Graph

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Interchangeable Biosimilars Market Regional Synopsis

On the basis of geographical analysis, the global interchangeable biosimilars market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Asia Pacific region is estimated to witness noteworthy growth over the forecast period on the back of advancement in the healthcare infrastructure, along with the growing number of researchers involved in R&D activities in the region. As per the data by the World Bank, there were 5331.15 researcher per million people in Japan, and 1307.121 per million people in China, as of 2018. On the other hand, the market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the growing emergence of new pharmaceutical companies over the past decade, along with high investment in medical research activities.

Interchangeable Biosimilars Market Share Graph

Get more information on this report: Request Sample PDF

The global interchangeable biosimilars market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

Market Segmentation

Our in-depth analysis of the global interchangeable biosimilars market includes the following segments:

By Disease Type

  • Crohn’s Disease
  • Ulcerative Colitis
  • Psoriasis
  • Diabetes
  • Cancer
  • Others

By Distribution Channel

  • Hospital
  • Retail Pharmacies
  • Others

Growth Drivers

  • Growing Prevalence of Diseases, such as, Cancer
  • Increasing Investment in Medical Research Activities

Challenges

  • Stringent Regulations regarding the Approval of Biosimilars

Top Featured Companies Dominating the Market

  • Biocon Limited
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis 
  • Mylan N.V.
  • Amgen Inc.
  • Coherus BioSciences, Inc.
  • Pfizer Inc.
  • Sandoz International GmbH
  • Merck & Co.
  • Boehringer Ingelheim group
  • Samsung Bioepis Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved